^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Esophageal Cancer

Related cancers:
11h
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=381, Recruiting, Hutchmed | Trial completion date: Sep 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IFNA1 (Interferon Alpha 1)
|
PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion
|
Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
12h
Trial completion
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel
12h
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (clinicaltrials.gov)
P1/2, N=232, Recruiting, AstraZeneca | Trial completion date: Apr 2025 --> Jul 2025 | Trial primary completion date: Jan 2025 --> Jul 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 expression
|
sabestomig (AZD7789)
13h
Oesophagectomy and Chest Wall and Respiratory Function (clinicaltrials.gov)
P=N/A, N=100, Recruiting, Imperial College London | N=150 --> 100 | Trial completion date: Jun 2023 --> Mar 2024 | Trial primary completion date: Jun 2023 --> Mar 2024
Enrollment change • Trial completion date • Trial primary completion date
14h
EDGE-Gastric: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (clinicaltrials.gov)
P2, N=360, Recruiting, Arcus Biosciences, Inc. | N=200 --> 360 | Trial completion date: Nov 2025 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154) • quemliclustat (AB680)
14h
Enrollment open • Combination therapy • Metastases
|
paclitaxel • docetaxel • irinotecan • izalontamab brengitecan (BL-B01D1)
14h
ABBIMUNE: A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (clinicaltrials.gov)
P1/2, N=54, Active, not recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Trial primary completion date: Jun 2023 --> Jun 2024
Trial primary completion date • Combination therapy • Metastases
|
Imfinzi (durvalumab) • Imjudo (tremelimumab)
15h
New trial
15h
KEYNOTE-877: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab (clinicaltrials.gov)
P1/2, N=323, Active, not recruiting, RAPT Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Sep 2024
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • tivumecirnon (FLX475)
16h
Screening and verification of hub genes in esophageal squamous cell carcinoma by integrated analysis. (PubMed, Sci Rep)
We found that CDC6 was upregulated in ESCC cell lines and patient tissues and was related to the clinicopathological characteristics of ESCC. In conclusion, this study identified hub genes and crucial biological pathways related to ESCC tumorigenesis and integrated analyses indicated that CDC6 may be a novel diagnostic and therapeutic target for ESCC.
Journal
|
CDC6 (Cell Division Cycle 6)
1d
Unraveling the causal role of immune cells in gastrointestinal tract cancers: insights from a Mendelian randomization study. (PubMed, Front Immunol)
These traits include "CCR2 on CD14- CD16+ monocyte," "CD19 on IgD+ CD38-," "CD19 on IgD+ CD38- naive," "CD25hi CD45RA+ CD4 not Treg AC," "CD27 on unsw mem," "CD28 on CD39+ activated Treg," and "CD45 on CD4+." This study elucidates a causal link between immune cells and gastrointestinal tract cancers at various sites through genetic investigation. The findings of this research open up new perspectives and resources for exploring tumor prevention strategies and immunotherapeutic targets.
Journal • Immune cell
|
CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • CCR2 (C-C Motif Chemokine Receptor 2) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
1d
PALOMA: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (clinicaltrials.gov)
P1, N=166, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2024 --> Oct 2024
Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR exon 20 insertion • EGFR exon 20 mutation
|
Leclaza (lazertinib) • amivantamab SC (Ami-LC)
1d
Google Location History Following Oesophagectomy and/or Gastrectomy (clinicaltrials.gov)
P=N/A, N=3, Completed, Imperial College London | Recruiting --> Completed | N=300 --> 3
Trial completion • Enrollment change
1d
REWARD: Resection of the Esophagus and Subsequent Weight Loss (clinicaltrials.gov)
P=N/A, N=30, Terminated, Imperial College London | Suspended --> Terminated; Funding stopped.
Trial termination • Surgery
1d
New trial
2d
Lymphatic endothelial cell-mediated accumulation of CD177+Treg cells suppresses antitumor immunity in human esophageal squamous cell carcinoma. (PubMed, Oncoimmunology)
Finally, we found that lymphatic endothelial cells are associated with CD177+ Treg cell accumulation in ESCC tumors, which are also decreased after anti-PD-1 immunotherapy plus chemotherapy. Our work identifies CD177+ Treg cell as a tumor-specific Treg cell subset and highlights their potential value as a prognostic marker of survival and response to immunotherapy and a therapeutic target in ESCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IL10 (Interleukin 10) • CD177 (CD177 Molecule)
|
CD177 expression
2d
Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma. (PubMed, Cancer Cell Int)
Collectively, these findings suggest that domperidone serves as an effective "multi-target" inhibitor of MEK1/2 and CDK4, offering potential benefits for the chemoprevention of ESCC.
Journal
|
CDK4 (Cyclin-dependent kinase 4) • SMAD3 (SMAD Family Member 3)
2d
Predictive and Carcinogenic Roles of Necroptosis-Related miR-425-5p and miR-16-5p in Esophageal Squamous Cell Carcinoma. (PubMed, Ann Clin Lab Sci)
The pro-carcinogenic role of miR-425-5p and miR-16-5p has been observed in esophageal squamous cell carcinoma.
Journal
|
MIR16 (MicroRNA 16) • MIR425 (MicroRNA 425)
|
miR-425 expression
2d
NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
P2, N=51, Suspended, Gustave Roussy, Cancer Campus, Grand Paris | N=112 --> 51 | Trial completion date: Mar 2027 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Mar 2024 --> Dec 2024
Enrollment change • Trial completion date • Trial suspension • Trial primary completion date • Pan tumor
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
|
HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
|
Zejula (niraparib) • Jemperli (dostarlimab-gxly)
2d
The Bacterial Composition of the Stomach in Reflux Disease (clinicaltrials.gov)
P=N/A, N=100, Active, not recruiting, Imperial College London | Recruiting --> Active, not recruiting | Trial completion date: Jan 2022 --> Dec 2024 | Trial primary completion date: Oct 2021 --> Dec 2024
Enrollment closed • Trial completion date • Trial primary completion date
2d
Enrollment open
2d
SG-ESCC: Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=35, Not yet recruiting, National Taiwan University Hospital
New P2 trial • Metastases
|
TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
Trodelvy (sacituzumab govitecan-hziy)
3d
Enrollment change • Trial primary completion date • Pan tumor
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • IL2 (Interleukin 2) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
|
DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
|
Tecentriq (atezolizumab) • Rubraca (rucaparib)
3d
NKX3.1 Expression in Non-Prostatic Tumors and Characterizing its Expression in Esophageal/Gastroesophageal Adenocarcinoma. (PubMed, Adv Anat Pathol)
This finding suggests that E/GE-ADC can sporadically stain positive for NKX3.1, introducing potential challenges in definitively determining the primary site of origin in certain clinical scenarios. Along with a literature review of NKX3.1 expression in other tumor types, our study provides additional important information about the extent to which this immunostain can be seen in E/GE-ADCs, which, to our knowledge, has not been reported.
Journal
|
NKX3-1 (NK3 homeobox 1)
3d
Phase classification • Combination therapy • Checkpoint inhibition • Metastases
|
Keytruda (pembrolizumab) • S-531011
3d
Enrollment open • Combination therapy • Metastases
|
Tevimbra (tislelizumab) • capecitabine • oxaliplatin • ASKB589
3d
A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer (clinicaltrials.gov)
P1, N=275, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
Trial completion date • Trial primary completion date • Metastases
|
ASP2138
4d
A Systems Biology Approach Unveils a Critical Role of DPP4 in Upper Gastrointestinal Cancer Patient Outcomes. (PubMed, J Environ Pathol Toxicol Oncol)
Overall, our findings suggest that DPP4 may serve as a substantial prognostic biomarker, a possible therapeutic target, as well as it can play a critical role in the regulation of immune cell invasion in patients with gastroesophageal (esophageal, gastroesophageal junction and gastric) cancer. KEY WORDS: DPP4, integrated analysis, GI cancer, gastroesophageal cancer, gastroesophageal junction, prognosis.
Journal
|
DPP4 (Dipeptidyl Peptidase 4)
4d
Galectin 7 leads to a relative reduction in CD4+ T cells, mediated by PD-1. (PubMed, Sci Rep)
Glycosylation of PD-1 has been reported to play a critical role in surface expression, stability, and interaction with its ligand PD-L1. This report further expands the significance of PD-1 glycosylation and suggests that galectin 7, a glycan-binding protein, interacts with the immune regulatory receptor PD-1 through glycosylation recognition.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
5d
Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers. (PubMed, Hematol Oncol Clin North Am)
Additionally, the emergence of trastuzumab deruxtecan (T-DXd) highlighted the potential of new pharmaceutical technologies to extend response, particularly for patients who have advanced beyond initial HER2-targeted therapies. This review aims to navigate through both the successes and challenges encountered historically, as well as promising current trials on innovative and transformative therapeutic strategies, including promising first-in-class and novel first-in-human agents.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
EGFR positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
5d
Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response. (PubMed, NPJ Precis Oncol)
Furthermore, when applied to biopsied treatment-naïve tumor samples, higher TLS ratios predicted a positive immunotherapy response across multiple cohorts, including specific therapies for esophageal squamous cell carcinoma, non-small cell lung cancer, and stomach adenocarcinoma. In conclusion, our deep learning-based approach offers an automated and reproducible method for TLS segmentation and quantification, highlighting its potential in predicting immunotherapy response and informing cancer prognosis.
Journal • IO biomarker
|
CXCL13 (Chemokine (C-X-C motif) ligand 13)
|
CXCL13 expression
6d
Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. (PubMed, Technol Cancer Res Treat)
Our findings indicate that this combination may be a potential neoadjuvant therapy regimen in this setting.
Journal • Metastases
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • paclitaxel • Loqtorzi (toripalimab-tpzi)
6d
Generation and characterization of mAb 61H9 against junctional adhesion molecule-a with potent antitumor activity. (PubMed, PeerJ)
The expression of BCL-2 and IκBα in the anti-JAM-A group were decreased in mice tumor tissues compared to the control group. Ultimately, a method for preparing high-yield JAM-A-Fc protein was created and a high affinity mAb against JAM-A with an antitumor effect was prepared.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NFKBIA (NFKB Inhibitor Alpha 2)
|
BCL2 expression
6d
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
FGFR2 overexpression • FGFR2b overexpression
|
Opdivo (nivolumab) • capecitabine • oxaliplatin • bemarituzumab (AMG 552)
6d
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
P1, N=35, Completed, Rahul Aggarwal | Active, not recruiting --> Completed | Phase classification: P1b --> P1
Trial completion • Phase classification • Combination therapy • Metastases
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • abexinostat (CG-781)
6d
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence (clinicaltrials.gov)
P=N/A, N=11, Terminated, Mayo Clinic | N=500 --> 11 | Active, not recruiting --> Terminated; Study's Principal Investigator no longer at the institution.
Enrollment change • Trial termination
6d
Identification and validation of prognostic and immunotherapeutic responses in esophageal squamous carcinoma based on hypoxia phenotype-related genes. (PubMed, Front Pharmacol)
In vitro experiments showed that the knockdown of PKP1 inhibited ESCC cell proliferation and migration. These findings suggest that the novel HPRscore and PKP1 may serve as prognostic tools and therapeutic targets for ESCC patients.
Journal • IO biomarker
|
PKP1 (Plakophilin 1)
6d
Radiogenomics in Aerodigestive Tract Cancers (clinicaltrials.gov)
P=N/A, N=139, Completed, Buddhist Tzu Chi General Hospital | Recruiting --> Completed | Trial completion date: Jul 2027 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023
Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
|
PD-L1 (Programmed death ligand 1)
6d
Assessing the Immunogenicity of pING-hHER3FL (clinicaltrials.gov)
P1, N=24, Recruiting, Herbert Lyerly | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
Trial completion date • Trial primary completion date
|
ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
ERBB3 expression
|
pING-hHER3FL
6d
Circular RNA circCHSY1 silencing inhibits the malignant progression of esophageal squamous cell carcinoma. (PubMed, Discov Oncol)
CircCHSY1 contributed to ESCC cell malignancy, and the underlying mechanism involved the circCHSY1/miR-1229-3p/TCTN1 axis, providing potential therapeutic targets for ESCC.
Journal • Circular RNA
|
MIR122 (MicroRNA 122)
6d
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) (clinicaltrials.gov)
P1/2, N=75, Terminated, Merck Sharp & Dohme LLC | Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; Business Reasons
Phase classification • Trial termination • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative
|
Keytruda (pembrolizumab) • Cavatak (gebasaxturev)
7d
18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. (PubMed, J Nucl Med)
Patients treated with frontline programmed death 1 inhibitors who had 18F-BMS-986229 accumulation in any lesions on PET imaging had longer progression-free survival than patients without tracer accumulation in any lesions (median progression-free survival, 28.4 vs. 9.9 mo), though the small sample size prevents any definitive conclusions. PD-L1 PET imaging was safe, feasible, and concordant with pathologic evaluation and offers a potential noninvasive tool to assess PD-L1 expression.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression